First-in-Class Breast Cancer Vaccine Potential: Anixa Biosciences is developing a first-in-class preventative vaccine for triple-negative breast cancer, a highly aggressive form with limited treatment options, offering a novel approach to cancer prevention.

Proprietary Oncolytic Virus Platform (CAdVax): Their patented CAdVax platform for oncolytic viruses is engineered to specifically target and destroy cancer cells while also stimulating an immune response, providing a unique therapeutic modality.

Differentiated CAR-T/NK Cell Therapy Expertise: Anixa possesses specialized knowledge and intellectual property in developing Chimeric Antigen Receptor (CAR) therapies, particularly focusing on natural killer (NK) cells, potentially offering advantages over traditional CAR-T cells such as improved safety profiles and broader applicability.